We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$53.6B
AUM Growth
+$2.66B
(+5.2%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
821
New
56
Increased
227
Reduced
258
Closed
253
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$86.2M |
| 2 |
Alcon
ALC
|
+$81.8M |
| 3 |
NVIDIA
NVDA
|
+$76M |
| 4 |
Corning
GLW
|
+$50.4M |
| 5 |
UnitedHealth
UNH
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$67.4M |
| 2 |
Factset
FDS
|
+$62M |
| 3 |
Euronet Worldwide
EEFT
|
+$42.3M |
| 4 |
Bank of America Series L
BAC.PRL
|
+$39.5M |
| 5 |
OPLN
Openlane
OPLN
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 17.74% |
| 3 | Financials | 11.65% |
| 4 | Healthcare | 11.2% |
| 5 | Communication Services | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
CVB Financial
CVBF
$3.99B
| $13.9M | 0.03% |
662,894
-34,152
| -5% | -$728K |
|
252
Ultragenyx Pharmaceutical
RARE
$2.55B
| $13.9M | 0.03% |
+219,254
| New | +$14M |
|
|
LOGM
253
DELISTED
LogMein, Inc.
LOGM
| $13.9M | 0.03% |
188,243
-6,062
| -3% | -$468K |
|
254
TriNet
TNET
$3.14B
| $13.8M | 0.03% |
+204,144
| New | +$13M |
|
|
ROIC
255
DELISTED
Retail Opportunity Investments Corp.
ROIC
| $13.8M | 0.03% |
805,827
-19,842
| -2% | -$344K |
|
256
Raymond James Financial
RJF
$34B
| $13.8M | 0.03% |
244,313
-12,577
| -5% | -$717K |
|
257
Clean Harbors
CLH
$16.3B
| $13.7M | 0.03% |
192,576
-4,597
| -2% | -$320K |
|
258
Western Alliance Bancorporation
WAL
$8.87B
| $13.7M | 0.03% |
306,056
+63,402
| +26% | +$2.83M |
|
|
MYOK
259
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $13.6M | 0.03% |
271,408
+35,529
| +15% | +$1.73M |
|
260
Cathay General Bancorp
CATY
$4.24B
| $13.6M | 0.03% |
378,065
-39,331
| -9% | -$1.4M |
|
261
Gray Television
GTN
$552M
| $13.5M | 0.03% |
822,753
-68,178
| -8% | -$1.35M |
|
262
Allegion
ALLE
$14.4B
| $13.4M | 0.03% |
120,989
-5,903
| -5% | -$590K |
|
|
JBGS
263
JBG SMITH
JBGS
$708M
| $13.4M | 0.03% |
339,784
-8,272
| -2% | -$340K |
|
264
Triumph Financial Inc
TFIN
$1.82B
| $13.3M | 0.02% |
457,503
-11,151
| -2% | -$332K |
|
|
CADE
265
DELISTED
Cadence Bank
CADE
| $13.3M | 0.02% |
456,642
-10,853
| -2% | -$315K |
|
266
MDU Resources
MDU
$4.32B
| $13M | 0.02% |
1,320,168
-32,729
| -2% | -$319K |
|
267
RB Global
RBA
$17.5B
| $13M | 0.02% |
389,874
-23,377
| -6% | -$800K |
|
268
Alamo Group
ALG
$2.05B
| $12.9M | 0.02% |
129,488
+38,495
| +42% | +$3.84M |
|
269
CubeSmart
CUBE
$9.41B
| $12.9M | 0.02% |
384,496
-6,625
| -2% | -$218K |
|
270
Five Below
FIVE
$13.5B
| $12.8M | 0.02% |
106,241
+30,512
| +40% | +$4.02M |
|
271
Conduent
CNDT
$264M
| $12.7M | 0.02% |
1,323,128
-125,218
| -9% | -$1.35M |
|
272
First Financial Bancorp
FFBC
$3.53B
| $12.7M | 0.02% |
523,564
-12,663
| -2% | -$304K |
|
273
Invesco QQQ Trust
QQQ
$484B
| $12.7M | 0.02% |
67,803
+7
| +0% | +$1.29K |
|
|
BMTC
274
DELISTED
Bryn Mawr Bank Corp
BMTC
| $12.6M | 0.02% |
338,815
-8,208
| -2% | -$307K |
|
275
Frontdoor
FTDR
$6.26B
| $12.6M | 0.02% |
290,084
-5,028
| -2% | -$193K |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2019 Portfolio in Review
As of Q2 2019, Loomis, Sayles & Company held 821 positions worth $53.6B, up 5.2% from $50.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loomis, Sayles & Company's Q2 2019 filing shows 56 new, 227 increased, 258 reduced and 253 closed positions. Its largest new stake was Alcon: 1,393,674 shares worth $86.5M. The largest sale was Novartis, an estimated $67.4M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q2 2019 buy was Alcon: 1,393,674 shares worth $86.5M.
- Loomis, Sayles & Company added most to Bristol-Myers Squibb in Q2 2019, an estimated $86.2M increase.
- Loomis, Sayles & Company's biggest Q2 2019 reduction was Novartis, cutting an estimated $67.4M.
- Loomis, Sayles & Company fully exited RingCentral in Q2 2019, selling an estimated $30.4M.
- Loomis, Sayles & Company's ten largest holdings make up 37% of its $53.6B portfolio in Q2 2019.
- Loomis, Sayles & Company opened 56 new positions and closed 253 in Q2 2019.
- Loomis, Sayles & Company's portfolio value rose 5.2% quarter-over-quarter to $53.6B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.